The Compound Report is an educational resource. Nothing on this site constitutes medical advice or encourages personal use of any compound. Always consult a qualified healthcare provider.
Educational reference only. Nothing on this page constitutes medical advice or encourages personal use of this compound. Always consult a qualified healthcare provider before any decision involving your health.
For 60 years, antidepressant pharmacology was dominated by monoamines — serotonin, norepinephrine, dopamine. The discovery that ketamine produces antidepressant effects within hours through a completely different system — glutamate — reset the entire field. TAK-653 is the oral, non-dissociative attempt to capture the same mechanism more cleanly.
The monoamine hypothesis of depression has been the dominant framework since the 1950s: depression arises from deficiency or dysregulation of serotonin, norepinephrine, or dopamine. The pharmacological corollaries — SSRIs, SNRIs, MAOIs, TCAs — all manipulate monoaminergic systems. They work for many patients. For a significant fraction — estimates range from 30-50% — they don't produce adequate relief. Treatment-resistant depression (TRD), defined as inadequate response to two or more adequately dosed antidepressant trials, affects tens of millions of people globally. The monoamine approach was not reaching them.
The ketamine breakthrough: in 2000, Berman et al. (Biol Psychiatry) published the first controlled study showing ketamine — an NMDA receptor antagonist — produced rapid antidepressant effects in hours in people with TRD. This was pharmacologically revolutionary: a completely different neurotransmitter system (glutamate, not monoamines), a completely different receptor type (ionotropic, not G-protein coupled), and a completely different time course (hours, not weeks). The question that followed: what exactly is ketamine doing downstream that produces the antidepressant effect, and can we access that downstream mechanism more directly without ketamine's side effects?
The AMPA receptor hypothesis: the mechanistic work that followed suggested that NMDA blockade by ketamine triggers a compensatory upregulation of AMPA receptor-mediated transmission. AMPA receptor activation in the hippocampus and prefrontal cortex then drives BDNF production via TrkB signaling — and BDNF-mediated neurogenesis and synaptic plasticity are increasingly recognized as the final common pathway through which multiple antidepressant mechanisms produce their clinical effect. The therapeutic corollary: if AMPA receptor upregulation is downstream of ketamine and mediates its benefit, then directly enhancing AMPA receptor activity (with a PAM) should produce antidepressant effects without needing NMDA blockade — and without ketamine's dissociative profile.
THE CENTRAL TENSION
TAK-653 (osavampator) is the most pharmacologically rational attempt to extract ketamine's antidepressant benefit without its mechanism liability. Ketamine works but cannot be taken at home, requires clinical supervision, produces dissociation, and has documented abuse potential — all of which limit its utility as a chronic antidepressant. An oral once-daily AMPA PAM that produces the same BDNF and plasticity changes through the downstream receptor without any of the dissociation would be a genuine clinical advance in antidepressant pharmacology. The Phase 2 SAVITRI data (September 2025) showed statistically significant antidepressant effects. The Phase 1 CNS pharmacodynamic data showed no dissociation, no body sway, no subjective drug effects. The compound appears to achieve the hypothesized clean profile. Phase 3 will determine whether the efficacy magnitude is sufficient for regulatory approval in a field where placebo response is notoriously high and clinical trials expensive.
TAK-653's antidepressant mechanism is through AMPA-mediated BDNF induction and synaptic plasticity — not through monoamine reuptake inhibition and not through dissociative receptor blockade. The clinical and community behavioral profile is consistent with this: gradual mood improvement over days to weeks (not acute euphoria or dissociation); increased motivation and engagement; reduced anhedonia; cognitive improvements in processing speed and working memory. Community users describe improvement in mood and cognitive function that feels 'clean' — no intoxication, no euphoria, no altered perception. This matches the Phase 1 CNS data showing no subjective drug effects.
The Phase 1 CNS data showed objectively measurable cognitive enhancement in healthy volunteers: increased saccadic peak velocity (eye movement processing speed) and Stroop test effects (executive function). These findings, combined with the BDNF-mediated synaptic plasticity mechanism, make TAK-653 pharmacologically interesting as a nootropic. Community use for cognitive enhancement (separate from the antidepressant application) appears to be growing. The mechanism — enhanced glutamatergic synaptic transmission in hippocampal and prefrontal circuits — is directly relevant to learning, memory, and executive function. Whether the Phase 2 antidepressant doses (1-3 mg) produce meaningful cognitive enhancement in non-depressed individuals has not been studied.
The Phase 1 CNS pharmacodynamic data specifically measured subjective drug effects using validated scales (Bowdle VAS, Bond-Lader VAS) and found no signal — no euphoria, no drug liking, no altered consciousness at either dose tested. The mechanism (AMPA PAM) does not directly activate reward pathways in the way that NMDA antagonists (ketamine) or dopaminergic compounds do. The absence of subjective drug effects is the key pharmacological basis for expecting low abuse liability. This does not mean dependence is impossible — psychological habituation to any mood-improving or cognitively enhancing compound can develop — but the pharmacological profile strongly suggests the risk is substantially lower than ketamine or stimulant-class alternatives.
The most important safety concern for any AMPA-potentiating compound is proconvulsant activity. The preclinical data showed a broad exposure margin between antidepressant-effective doses and seizure-inducing doses. Phase 1 human data at doses up to 6mg showed no seizures or EEG abnormalities. The Phase 2 doses of 1-3mg are well below the doses where any human seizure signal has been observed. However: the seizure risk at very high doses or in seizure-susceptible individuals (prior seizure history, proconvulsant medications) has not been fully characterized in humans. This is the most important contraindication for community use: a personal history of seizure disorder or use of medications that lower the seizure threshold (tramadol, bupropion, certain antibiotics) warrants extreme caution or complete avoidance.
AMPA receptors (alpha-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid receptors) are tetrameric ionotropic glutamate receptors assembled from combinations of four subunit types: GluA1 (GluR1), GluA2 (GluR2), GluA3 (GluR3), and GluA4 (GluR4). They are the primary mediators of fast excitatory synaptic transmission throughout the CNS — when glutamate binds, AMPA receptors open rapidly, allowing Na+ (and to a lesser extent Ca2+) influx that depolarizes the postsynaptic membrane. This AMPA-mediated depolarization then removes the Mg2+ block from adjacent NMDA receptors, allowing NMDA receptor activation and Ca2+ influx for longer-term synaptic changes. AMPA receptors are therefore the first step in excitatory synaptic signaling and the gateway to the downstream plasticity processes that NMDA receptors mediate.
TAK-653 is a positive allosteric modulator (PAM) of AMPA receptors with selective potency at GluR1-containing receptors. Allosteric modulation means binding a site geometrically separate from the glutamate binding site — not the orthosteric (natural ligand) site. This has a critical pharmacological consequence: TAK-653 does not activate the receptor alone. It requires the natural ligand (glutamate) to be present for any receptor activation to occur. This synaptic activity-dependence means TAK-653 amplifies naturally-occurring synaptic glutamate signals without creating artificial glutamate activity where it doesn't exist. The net effect is that TAK-653 increases the magnitude of glutamatergic synaptic responses — AMPA receptor opening is larger or longer when glutamate binds in the presence of TAK-653 — but only at synapses where glutamate is being released. This is a more targeted approach than direct AMPA agonism, which would cause broad, non-synaptic glutamate receptor activation.
Enhanced AMPA-mediated glutamatergic transmission produces antidepressant effects through several converging pathways: (1) BDNF induction — increased synaptic activity in hippocampal and prefrontal circuits activates CREB-dependent transcription of BDNF (brain-derived neurotrophic factor); BDNF promotes neuronal survival, dendritic growth, synaptogenesis, and neurogenesis in the hippocampus; BDNF levels are reduced in depression and restored by effective antidepressant treatment across multiple mechanism classes; (2) Synaptic strengthening — enhanced AMPA transmission at specific synapses leads to LTP (long-term potentiation)-like plasticity processes that strengthen dysfunctional neural circuits involved in mood, reward, and stress response regulation; (3) mTOR activation — increased AMPA signaling activates the mTOR pathway in prefrontal cortex, driving protein synthesis needed for synaptogenesis; this is the same pathway activated by ketamine's antidepressant mechanism. The selective and activity-dependent nature of AMPA PAM activity means these plasticity effects are concentrated where glutamate is naturally being released — at the synapses that are already engaged in the circuits most relevant to mood regulation.
A fundamental concern with any AMPA receptor potentiator is proconvulsant activity — excess glutamatergic excitation is the mechanism of seizures, and non-selective AMPA agonists and earlier ampakines showed narrow therapeutic-to-seizure windows. The preclinical development of TAK-653 specifically addressed seizure risk: the Hara et al. (2021) preclinical paper documented a 'broad exposure margin against seizures' — meaning the dose required to produce seizure activity was substantially higher than the dose required for antidepressant effect. This safety separation is a critical design achievement: earlier ampakine compounds failed in part because they lacked this margin. TAK-653's selective GluR1 PAM activity (rather than broader AMPA subunit coverage) may contribute to this favorable seizure margin. In the Phase 1 human study, no seizure activity was observed at doses up to 6mg (substantially above the 1-3mg Phase 2 doses).
TAK-653 / osavampator has human evidence from Phase 1 CNS pharmacodynamics and Phase 2 efficacy — with the most recent data from Psych Congress September 2025. This is a compound with active clinical development and fresh positive data.
Dijkstra F, O'Donnell P, Klaassen E, et al. (2022). Central nervous system effects of TAK-653, an investigational AMPAR positive allosteric modulator in healthy volunteers. Translational Psychiatry. 12(1):429. PMC9509332. Design: randomized, double-blind, placebo-controlled, three-way crossover; n=24 healthy volunteers; three conditions (placebo, TAK-653 0.5 mg, TAK-653 6 mg); NeuroCart CNS biomarker battery. KEY FINDINGS: No body sway (no vestibular/balance impairment — the primary marker of CNS sedation/dissociation). No subjective drug effects on Bowdle and Bond-Lader Visual Analogue Scales (no 'high', no dissociation, no altered consciousness). TAK-653 0.5 mg increased saccadic peak velocity (SPV) — a marker of cognitive activation/processing speed. The Stroop test was affected — consistent with cognitive enhancement at the processing level. The CNS profile was entirely distinct from NMDA antagonists (ketamine) or benzodiazepines — no sedation, no dissociation, actually positive cognitive markers. This study is the primary evidence that TAK-653 achieves the clean CNS profile that distinguishes it from ketamine and justifies oral outpatient development.
The original Takeda-sponsored Phase 2a study in treatment-resistant depression enrolled patients with inadequate response to prior antidepressant treatments. This study contributed to the decision to advance the compound and license it to Neurocrine for broader development. The specific results of NCT03312894 have been described in investor presentations and regulatory submissions but the full peer-reviewed publication was not yet available in the public literature as of the Neurocrine SAVITRI presentations. It established the efficacy signal that justified the SAVITRI Phase 2 program.
The SAVITRI Phase 2 study results were presented at the 38th annual Psych Congress on September 22, 2025, by Neurocrine Biosciences. Study design: dose-finding, randomized, double-blind, placebo-controlled; n=183 adults aged 18-65 with MDD who had inadequate response to current antidepressant treatment; 2:1:1 randomization to placebo, osavampator 1 mg once daily, or osavampator 3 mg once daily; 8-week treatment period. Primary finding: osavampator demonstrated statistically significant and clinically meaningful improvements in depression severity vs placebo. Both doses were well-tolerated. The presentation was honored with the 2025 Poster Award at the conference. The full peer-reviewed publication of SAVITRI results was anticipated in late 2025 or 2026. This is the most current clinical evidence for the compound and represents the primary basis for Phase 3 planning.
Hara H, Suzuki A, Kunugi A, et al. (2021). TAK-653, an AMPA receptor potentiator with minimal agonistic activity, produces an antidepressant-like effect with a favorable safety profile in rats. Pharmacology, Biochemistry and Behavior. 211:173289. Key preclinical findings: antidepressant-like activity across multiple rodent behavioral models; procognitive effects; broad seizure safety margin (dose producing antidepressant effect is substantially lower than dose producing seizures); BDNF induction confirmed in brain tissue; minimal direct agonistic activity (confirms PAM rather than agonist profile — critical for safety).
Study
Population
Design
Grade
Key Finding
Hara et al. 2021 (Pharmacol Biochem Behav)
Rats
Preclinical behavioral; BDNF assay
C
Antidepressant-like behavior; procognitive; broad seizure margin; BDNF induction
Dijkstra et al. 2022 (Transl Psychiatry; PMC9509332)
24 healthy volunteers
Phase 1; 3-way crossover; NeuroCart battery
B
No body sway; no dissociation; no subjective drug effects; SPV and Stroop activation at 0.5mg — clean CNS profile confirmed
Phase 2a TRD (NCT03312894)
TRD patients
Phase 2a DBRCT
B
Antidepressant efficacy signal in TRD; basis for Neurocrine license; full publication pending
Phase 2 SAVITRI (NCT05203341; Psych Congress Sept 2025)
183 MDD adults; inadequate antidepressant response
Phase 2 DBRCT; n=183; 8 weeks; 1mg and 3mg vs placebo; dose-finding
B
Statistically significant and clinically meaningful depression severity improvement vs placebo; well-tolerated; both doses positive; 2025 Poster Award
The comparison to ketamine is the most practically important clinical question for anyone considering TAK-653 for treatment-resistant depression. The two compounds target the same downstream system through different upstream mechanisms.
Feature
TAK-653 / Osavampator
Ketamine / Esketamine (Spravato)
Primary mechanism
AMPA receptor PAM — enhances glutamatergic transmission
NMDA receptor antagonist — blocks glutamate at NMDA receptors
Glutamate pathway position
Acts directly on AMPA receptor (downstream of NMDA)
Acts at NMDA receptor; AMPA upregulation follows downstream
BDNF induction
Yes — via enhanced AMPA-mediated synaptic activity
Yes — same downstream pathway, different upstream entry
Route of administration
Oral, once daily
IV (ketamine) or intranasal (esketamine/Spravato)
Dissociation
None observed in Phase 1 or community reports
Prominent; requires clinical monitoring for 2 hours post-dose
Abuse potential
Not identified — no subjective drug effects
Significant ketamine abuse well-documented; Spravato is REMS-restricted
Onset of antidepressant effect
Days to weeks (Phase 2: 8 weeks primary endpoint)
Hours (ketamine's signature feature)
Clinical supervision required
No — oral, outpatient
Yes — Spravato REMS requires in-clinic administration and monitoring
Approval status
Phase 2 complete; Phase 3 pending; NOT approved
Esketamine (Spravato) FDA-approved 2019 for TRD/MDD
Cost accessibility
Research chemical currently
Spravato: $800-1,000+ per treatment session in clinic
Seizure risk
Low — broad safety margin established preclinically
Not a primary concern at antidepressant doses
The honest summary of the comparison: ketamine/esketamine have the faster onset and the FDA approval. TAK-653 has the cleaner profile and the oral route. For patients who need antidepressant effect within hours (suicidal crisis, acute severe episode), ketamine's speed advantage is irreplaceable and clinically critical. For patients who need chronic antidepressant augmentation — the much larger population — an oral outpatient option without dissociation and without the REMS-clinic requirement would be far more accessible and practicable. If Phase 3 confirms SAVITRI's efficacy signal, TAK-653 could become the preferred chronic glutamatergic antidepressant augmentation option.
The Phase 2 SAVITRI study used 1 mg and 3 mg once-daily oral dosing. Both doses showed efficacy. Community protocols are extrapolated directly from these Phase 2 doses — this is a better-anchored starting point than most research chemicals in this book, where dosing is typically extrapolated from animal data. The community-used doses (1-3 mg/day oral) are the same doses that produced both antidepressant efficacy in Phase 2 and no adverse CNS effects in Phase 1.
Parameter
Details
Form
Oral small molecule; tablet or capsule from research vendors
Starting dose
1 mg/day — the lower Phase 2 dose; well-tolerated in SAVITRI
Target dose
1-3 mg/day — both Phase 2 doses showed efficacy
Frequency
Once daily; morning preferred (consistent with stimulatory cognitive effects)
Onset
Phase 2 primary endpoint was 8 weeks; community reports suggest mood effects in 2-4 weeks
Cycling
No established cycling protocol; Phase 2 used continuous 8-week treatment; community typically continuous
Storage
Room temperature; standard small molecule conditions
Contraindications
Seizure history; concurrent proconvulsant medications (tramadol, bupropion, certain antibiotics, antipsychotics that lower seizure threshold)
The same guidance from the PE-22-28 chapter applies: TAK-653 should not be the primary or sole treatment for clinical depression without physician oversight. The Phase 2 context was adjunctive treatment — added to an existing antidepressant, not replacing it. Community self-administration as a standalone antidepressant for moderate-to-severe MDD carries the same risk as any research chemical depression self-treatment: if the compound underdoses, the underlying depression goes untreated; if there are quality issues with the research chemical, the dose is uncertain. For mild mood improvement and cognitive enhancement in non-clinically-depressed individuals, the risk profile is more favorable. For anyone with clinical MDD or TRD: a physician-supervised clinical trial (searching ClinicalTrials.gov for NCT05203341 follow-on Phase 3 studies) is the most appropriate access pathway.
TAK-653 and ketamine both affect glutamatergic neurotransmission but through opposite mechanisms. Ketamine blocks NMDA receptors — reducing glutamate's ability to activate those receptors. TAK-653 enhances AMPA receptors — increasing glutamate's effect when it binds those receptors. One reduces glutamatergic tone (acutely, at NMDA); the other increases it (at AMPA). The downstream consequences converge on BDNF induction and synaptic plasticity, but the upstream pharmacology, the CNS profile (dissociation vs none), the abuse potential (significant vs none), and the route of administration (IV/intranasal vs oral) are categorically different.
The absence of subjective drug effects — no high, no dissociation, no altered perception — is a pharmacological feature, not a sign of ineffective dosing. AMPA PAM activity enhances the functional efficiency of glutamatergic synaptic transmission without producing perceptual disturbance or reward pathway activation. The cognitive enhancement (increased saccadic velocity, Stroop effects) documented in healthy volunteers is objectively measurable even in the absence of subjective experience. The antidepressant effect documented in Phase 2 occurred with the same clean CNS profile. Not feeling a compound does not mean it isn't working.
TAK-653 is one of the better-evidenced research chemicals in this book from a human safety perspective: Phase 1 in 24 healthy volunteers (published Translational Psychiatry 2022); Phase 2 in 183 MDD patients (SAVITRI, Psych Congress September 2025); both positive. The community doses (1-3 mg/day) are the same as the Phase 2 doses that showed both efficacy and safety in human clinical trials. Compared to compounds in this book with only mouse behavioral data, TAK-653 has meaningful human safety and CNS profile data supporting its use at those doses. It remains unapproved and the full peer-reviewed SAVITRI publication is pending — but the evidence base is not thin.
TAK-653 and earlier ampakines (CX-516, CX-614, Farampator) share the AMPA PAM class mechanism but are structurally distinct compounds with different subunit selectivities, potencies, and safety margins. CX-516 (the original ampakine) was less selective, less potent, had narrower seizure margins, and produced GI adverse events that limited its utility. TAK-653 was specifically designed to overcome these limitations — the Hara 2021 preclinical paper documented broad seizure margin and minimal agonistic activity as key differentiators from earlier ampakines. Do not extrapolate CX-516 or ampakine-class adverse event data directly to TAK-653 without noting the structural and pharmacological differences.
Dijkstra F, O'Donnell P, Klaassen E, et al. (2022). Central nervous system effects of TAK-653, an investigational alpha-amino-3-hydroxy-5-methyl-4-isoxazole receptor (AMPAR) positive allosteric modulator in healthy volunteers. Translational Psychiatry. 12(1):429. PMC9509332. doi:10.1038/s41398-022-02148-w. [Phase 1 CNS pharmacodynamics; n=24 healthy volunteers; 3-way crossover; NeuroCart battery; no body sway; no subjective drug effects; SPV and Stroop activation; the primary human safety and CNS profile paper establishing clean profile vs ketamine.]
Neurocrine Biosciences. (September 22, 2025). Osavampator (NBI-1065845/TAK-653) Demonstrates Statistically Significant and Clinically Meaningful Improvements in Depression Severity and is Well Tolerated in Adults with Major Depressive Disorder: Phase 2 SAVITRI Results. Poster presentation at 38th Annual Psych Congress. Awarded 2025 Poster Award. [NCT05203341; n=183 MDD adults; 8 weeks; 1mg and 3mg once daily vs placebo; 2:1:1 randomization; both doses met primary endpoint; well-tolerated; positive dose-finding results for Phase 3 planning.]
Hara H, Suzuki A, Kunugi A, Tajima Y, Yamada R, Kimura H. (2021). TAK-653, an AMPA receptor potentiator with minimal agonistic activity, produces an antidepressant-like effect with a favorable safety profile in rats. Pharmacology, Biochemistry and Behavior. 211:173289. doi:10.1016/j.pbb.2021.173289. [Preclinical antidepressant-like behavior; procognitive activity; broad seizure safety margin; BDNF induction; minimal agonistic activity establishing PAM profile; Takeda group.]
Kimura H, et al. (2022). Role of the AMPA receptor in antidepressant effects of ketamine and potential of AMPA receptor potentiators as a novel antidepressant. Neuropharmacology. 223:109320. doi:10.1016/j.neuropharm.2022.109320. [Mechanistic context paper; AMPA receptor role downstream of ketamine's NMDA block; rationale for AMPA PAM approach as ketamine mechanism capture; Takeda group.]
TAK-653 is the most clinically rational novel antidepressant mechanism in this book — an oral, non-dissociative approach to the glutamatergic antidepressant pathway that ketamine demonstrated was pharmacologically accessible. Phase 2 SAVITRI delivered positive results in September 2025. Phase 3 is the next frontier.
The honest summary: TAK-653 achieves what the antidepressant field has been trying to achieve since ketamine demonstrated the glutamate pathway's clinical relevance in 2000 — an oral, outpatient-appropriate, non-dissociative way to produce AMPA receptor-mediated BDNF induction and synaptic plasticity. The Phase 1 CNS data cleanly established the absence of dissociation, body sway, and subjective drug effects. The Phase 2 SAVITRI data (September 2025) established statistically significant antidepressant efficacy. The compound is being actively developed by Neurocrine, which received exclusive global rights from Takeda, and Phase 3 planning is the logical next step. For community users: the doses are Phase-2-validated (1-3 mg/day oral), the CNS profile is established, the primary safety concern is seizure threshold (contraindicated with seizure history or proconvulsant medications), and the compound is well-positioned as perhaps the most evidence-supported research chemical nootropic/antidepressant option in this book for mood and cognitive enhancement applications.
— End of TAK-653 / Osavampator —
THE PEPTIDE BIBLE | TAK-653 (Osavampator) | For Research & Educational Purposes Only
TAK-653 (INN: osavampator; Neurocrine: NBI-1065845): selective AMPA receptor positive allosteric modulator (AMPA-PAM). Oral, once-daily small molecule. Not a peptide. Developed by Takeda Pharmaceutical; licensed exclusively to Neurocrine Biosciences (worldwide ex-Japan). Not FDA-approved as of mid-2026. MECHANISM: AMPA-PAM binds allosteric site on GluR1/GluA1 subunit; amplifies glutamate-mediated AMPA receptor responses without directly activating the receptor; activity-dependent (requires glutamate to be present); downstream effects: enhanced glutamatergic transmission → BDNF induction via TrkB/CREB → hippocampal neurogenesis + synaptic plasticity + LTP = antidepressant and procognitive effects. SAME DOWNSTREAM PATHWAY as ketamine but via different entry point (AMPA vs NMDA). GLUTAMATE HYPOTHESIS: ketamine (NMDA antagonist) triggers downstream AMPA upregulation as part of antidepressant mechanism; TAK-653 addresses AMPA receptor directly without NMDA blockade = antidepressant effect without dissociation. PHASE 1 (Dijkstra et al. 2022, Transl Psychiatry, PMC9509332): n=24 healthy volunteers; 3-way crossover; NeuroCart battery; 0.5mg and 6mg; NO body sway; NO subjective drug effects (B-VAS, BL-VAS); NO dissociation; SPV increased at 0.5mg (cognitive activation marker); Stroop effects. Establishes clean CNS profile distinguishing from ketamine. PHASE 2 TRD (NCT03312894, Takeda, 2021): positive efficacy signal in TRD; basis for Neurocrine license. PHASE 2 SAVITRI (NCT05203341; Psych Congress September 22, 2025): n=183 MDD adults; inadequate antidepressant response; 2:1:1 placebo/1mg/3mg; 8 weeks; STATISTICALLY SIGNIFICANT AND CLINICALLY MEANINGFUL improvements in depression severity; well-tolerated; 2025 Psych Congress Poster Award. PRECLINICAL (Hara 2021, Pharmacol Biochem Behav): antidepressant behavior; procognitive; broad seizure margin; BDNF induction; minimal agonistic activity. COMMUNITY: 1-3 mg/day oral (Phase 2 validated doses); morning preferred; no subjective drug effects expected; antidepressant onset 2-4 weeks; cognitive enhancement at lower doses. SEIZURE CONTRAINDICATION: history of seizure disorder or concurrent proconvulsant medications — absolute contraindication. vs KETAMINE: ketamine = NMDA antagonist, fast onset (hours), dissociative, IV/intranasal, REMS clinic, abuse potential; TAK-653 = AMPA-PAM, weeks onset, no dissociation, oral, no supervision needed, no abuse liability. vs SSRI: TAK-653 = glutamatergic (AMPA→BDNF); SSRIs = monoaminergic (SERT block); different mechanisms; TAK-653 not competing with SSRIs but augmenting them (adjunctive Phase 2 design). WADA: not listed. No HPTA. Not C4 dependency concern. MDD/TRD application: physician oversight recommended; clinical trial is preferred access pathway.
A Structural Modification of Semax With No Published Studies of Its Own. Being Sold as 'The Most Potent Semax Analog.' Every Claim Belongs to Its Parent Compound.
The Compound That Raises NAD+ By Stopping the Body From Destroying It. NNMT: The Enzyme That Wastes Nicotinamide. Fat Loss Without Food Restriction in Mice. The Neelakantan Group's Research Tool Repurposed as a Longevity Drug. Zero Human Trials. 100 mg/Day Community Dose Extrapolated From Mouse IP Injections. The 1-MNA Question: The Metabolite You're Blocking Has Protective Roles in Liver and Kidney. A 2025 Cell/TPS Review Calls for Clinical Translation. Clinics Already Prescribing It Without FDA Ruling on Safety.
Six Human Clinical Trials. 900+ Participants. Safety Indistinguishable From Placebo. Primary Fat Loss Endpoint Failed. WADA Banned. FDA Rejected for Compounding. The Community Uses It Anyway at Doses That Never Worked in the Trials.